Photo from wikipedia
The primary aim of this study was to gain insight in the safety profile of the new antidiabetic agents glucagon‐like peptide‐1 (GLP‐1) agonists and dipeptidyl peptidase‐4 (DPP‐4) inhibitors in daily… Click to show full abstract
The primary aim of this study was to gain insight in the safety profile of the new antidiabetic agents glucagon‐like peptide‐1 (GLP‐1) agonists and dipeptidyl peptidase‐4 (DPP‐4) inhibitors in daily practice. The secondary aim was to compare reported adverse drug reactions (ADRs) with information described in the Summary of Product Characteristics (SPC) and to generate knowledge about characteristics, like time to onset and outcome of ADRs. This knowledge is important for drug regulators and clinical practice to understand and manage ADRs better.
Journal Title: Pharmacoepidemiology and Drug Safety
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!